1. |
March WA, Moore VM, Willson KJ, et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod, 2010, 25(2): 544-551.
|
2. |
Chang WY, Knochenhauer ES, Bartolucci AA, et al. Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertil Steril, 2005, 83(6): 1717-1723.
|
3. |
Fatemi HM, Garcia-Velasco J. Avoiding ovarian hyperstimulation syndrome with the use of gonadotropin-releasing hormone agonist trigger. Fertil Steril, 2015, 103(4): 870-873.
|
4. |
Meyer L, Murphy LA, Gumer A, et al. Risk factors for a suboptimal response to gonadotropin-releasing hormone agonist trigger during in vitro fertilization cycles. Fertil Steril, 2015, 104(3): 637-642.
|
5. |
Humaidan P, Kol S, Papanikolaou EG, et al. GnRH agonist for triggering of final oocyte maturation: time for a change of practice. Hum Reprod Update, 2011, 17(4): 510-524.
|
6. |
Nelson SM. Prevention and management of ovarian hyperstimulation syndrome. Thromb Res, 2017, 151(Suppl 1): S61-S64.
|
7. |
Mocanu E, Redmond ML, Hennelly B, et al. Odds of ovarian hyperstimulation syndrome (OHSS)-time for reassessment. Hum Fertil (Camb), 2007, 10(3): 175-181.
|
8. |
Vlahos NF, Gregoriou O. Prevention and management of ovarian hyperstimulation syndrome. Ann N Y Acad Sci, 2006, 1092: 247-264.
|
9. |
Engmann L, DiLuigi A, Schmidt D, et al. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril, 2008, 89(1): 84-91.
|
10. |
Youssef MA, Van der Veen F, Al-Inany HG, et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev, 2014, (10): CD008046.
|
11. |
Babayof R, Margalioth EJ, Huleihel M, et al. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Hum Reprod, 2006, 21(5): 1260-1265.
|
12. |
Griesinger G, von Otte S, Schroer A, et al. Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective, observational proof-of-concept study. Hum Reprod, 2007, 22(5): 1348-1352.
|
13. |
Manzanares MA, Gómez-Palomares JL, Ricciarelli E, et al. Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol levels. Fertil Steril, 2010, 93(4): 1215-1219.
|
14. |
Chen ZJ, Shi Y, Sun Y, et al. Fresh versus frozen embryos for infertility in the polycystic ovary syndrome. N Engl J Med, 2016, 375(6): 523-533.
|